Asciminib is the main study medicine in this trial. It is taken by mouth and is being continued in people who already used it in a previous study and were thought to still benefit from it. The trial is mainly looking at how safe long-term use of this medicine is, including any serious side effects or other unwanted effects over time.

Nilotinib is another oral cancer medicine included in the study group. It is used as an active treatment option for people with certain blood cancers, and the trial includes participants who may have received this medicine before or who are being followed while on it. The study helps monitor how safe it is when used over a longer period.

Dasatinib is an oral treatment used for some types of leukemia. In this trial, it is one of the active medicines that participants may have been receiving in parent studies before rolling over into this long-term safety study. Its role here is to continue treatment and watch for side effects during ongoing use.

Imatinib is an oral medicine used to treat certain blood cancers. It is included as an active treatment option in the study for participants who were already taking it in earlier studies. The trial follows patients who stay on this medicine to better understand its long-term safety and tolerability.

Bosutinib is an oral cancer medicine that may be used in people with certain leukemia types. It appears in the study as another active treatment that participants may continue from a previous trial. The study is not testing whether it works better, but rather tracking safety while treatment continues over time.

Chronic myelogenous leukemia – A cancer of the blood and bone marrow that begins with too many immature white blood cells. It usually develops slowly at first, then can progress through a more active phase and, in some cases, to a more advanced phase with faster growth of abnormal cells. The disease may cause the bone marrow to make fewer normal blood cells over time. Philadelphia chromosome-positive acute lymphoblastic leukemia – A fast-growing cancer of the blood and bone marrow that starts from very early lymphoid cells. It develops quickly as abnormal cells build up and crowd out normal blood cells. The disease can worsen as these immature cells continue to multiply and spread within the marrow and blood.